Trial · NCT04659109
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
NCT04659109, Phase 2, Completed, Acticor Biotech
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19. Trials, record NCT04659109. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04659109
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
- NCT number
- NCT04659109
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 60 participants, actual
- Lead sponsor
- Acticor Biotech
- Conditions
- SARS-CoV Infection, Acute Respiratory Distress Syndrome, COVID-19, ARDS
- Interventions
- glenzocimab, Placebo
- First posted
- 2020-12-09
- Last updated
- 2021-09-13
- Other registries' IDs
- eudract:2020-002733-15
Source ClinicalTrials.gov
Registered outcomes36
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression from moderate to severe respiratory distress assessed at Day 4 | Day 4 | Progression from moderate to severe assessed at Day 4 is a composite failure endpoint defined as the occurrence of at least one of the following failure events : * Respiratory rate (RR) ≥ 30/min, or * Oxygen Saturation (SpO2) ≤ 93% in resting state, or * Oxygen Pressure/ Inspired fraction (PaO2/FiO2) ≤ 200mmHg * Death occurring prior to or on Day 4 |
| Secondary | All cause mortality at day 40 | Day 40 (maximum) | |
| Secondary | WHO-COVID-19 Scale | Up to Day 40 | WHO COVID-19 Ordinal Scoring Scale is 9 point ordinal scale |
| Secondary | NEWS-2 Scale | Up to Day 40 | Determines the degree of illness of a patient and prompts critical care intervention (recommended by NHS over original NEWS): total possible score ranges from 0 to 20. The higher the scores the greater the clinical risk. |
| Secondary | Respiratory Rate status (RR) | Up to Day 40 | Respiratory Rate status defined as:: o Normal:\<20/min, * Mild:20/min≤RR\<24/min, * Moderate:24/min≤RR\<30/min, o Severe:≥30/min, * Death. |
| Secondary | Hypoxemia status | Up to Day 40 | Hypoxemia status defined as:: o Normal:\>300mmHg, * Mild: 200 mmHg \< PaO2/FiO2 ≤ 300 mmHg, * Moderate:100mmHg\<PaO2/FIO2≤200mmHg, o Severe:PaO2/FIO2≤100mmHg, * Death. |
| Secondary | SpO2 status | Up to Day 40 | SpO2 status defined as: o Normal:\>95% * Mild:93%\<SpO2≤95%, * Moderate:90%\<SpO2≤93%, o Severe:≤90%, * Death. |
| Secondary | CHEST CT-Scan (or in exceptional cases, chest radiogram) | Day 4 | |
| Secondary | Oxygen-free days | Up to Day 40 | |
| Secondary | Admission to the ICU | Up to Day 40 |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04659109
GET https://conductscience.org/api/trials/v1/NCT04659109/registered?page=2